Gastroenterology · Hepatobiliary Malignancy
The facts most likely to be tested
Press 1–5 to rate · ↑↓ to navigate
Chronic Hepatitis B infection is the most common worldwide risk factor for Hepatocellular Carcinoma (HCC), even in the absence of cirrhosis.
Cirrhosis from any etiology, particularly Hepatitis C and alcohol-associated liver disease, serves as the primary predisposing condition for HCC development in the United States.
Surveillance for high-risk patients involves abdominal ultrasound every 6 months, combined with alpha-fetoprotein (AFP) testing.
The classic triphasic CT scan or MRI demonstrates arterial phase hyperenhancement followed by venous phase washout.
Alpha-fetoprotein (AFP) is the most commonly utilized tumor marker, though its sensitivity and specificity are insufficient for diagnostic confirmation alone.
Surgical resection or liver transplantation (Milan criteria), along with thermal ablation of tumors under 3 cm, offers curative intent in patients with early-stage disease.
Aflatoxin B1 exposure from *Aspergillus* species is a potent environmental carcinogen that acts synergistically with Hepatitis B to increase HCC risk.
Vignette unlocked
A 58-year-old male with Child-Pugh class B Hepatitis C cirrhosis and clinically significant portal hypertension presents for a routine follow-up. He is asymptomatic, but a surveillance abdominal ultrasound reveals a 2.5 cm solitary liver mass. A subsequent triphasic CT scan shows arterial phase hyperenhancement of the lesion with venous phase washout. His alpha-fetoprotein (AFP) level is elevated at 450 ng/mL.
What is the most appropriate next step in management?
Liver transplantation
The patient meets the diagnostic criteria for HCC via imaging (arterial enhancement and venous washout) in the setting of cirrhosis; given his early-stage solitary lesion, he is a candidate for curative-intent liver transplantation per the Milan criteria.
Full handout
High yield triage
Etiology / Epidemiology
Primary malignancy of hepatocytes; cirrhosis (HBV, HCV, alcohol, MASH) is the primary risk factor.
Clinical Manifestations
Often asymptomatic until advanced; look for decompensated cirrhosis and palpable abdominal mass.
Diagnosis
Multiphasic (triphasic) CT/MRI showing arterial enhancement with venous washout is diagnostic by LI-RADS criteria; AFP raises suspicion but is no longer a diagnostic criterion.
Treatment
Surgical resection, thermal ablation, or liver transplantation for early-stage disease; atezolizumab + bevacizumab (or nivolumab + ipilimumab) is first-line systemic therapy for advanced disease.
Prognosis
Poor overall survival; BCLC staging drives prognosis and treatment selection, with the Child-Pugh score assessing hepatic reserve within it.
Full handout
Epidemiology & Etiology
Most cases arise in the setting of chronic liver disease, specifically Hepatitis B (even without cirrhosis) and Hepatitis C. Other major drivers include metabolic dysfunction-associated steatohepatitis (MASH), alcohol-associated liver disease, and hereditary hemochromatosis; Wilson disease carries a comparatively low HCC risk. Chronic exposure to aflatoxin (from *Aspergillus*) is a classic board-relevant environmental trigger.
Pertinent Anatomy
The liver's dual blood supply (portal vein and hepatic artery) dictates the tumor's vascularity. HCC is typically hypervascular, receiving the majority of its blood supply from the hepatic artery, which allows for diagnostic imaging differentiation.
Pathophysiology
Chronic inflammation leads to hepatocyte injury, regeneration, and eventual fibrosis/cirrhosis. Repeated cycles of injury and repair promote genetic mutations, specifically in the p53 tumor suppressor gene. The tumor often invades the portal vein, leading to portal hypertension and rapid clinical deterioration.
Clinical Manifestations
Patients often present with cachexia, weight loss, and right upper quadrant pain. Look for sudden worsening of ascites or variceal hemorrhage in a previously stable cirrhotic patient. A palpable liver mass or a new-onset bruit over the liver are highly specific findings.
Diagnosis
Surveillance for high-risk patients involves ultrasound plus AFP every 6 months. Diagnosis is confirmed via multiphasic (triphasic) CT or MRI demonstrating arterial phase hyperenhancement and delayed venous washout. AFP is no longer a diagnostic criterion at any threshold, and biopsy is reserved for lesions that do not meet LI-RADS imaging criteria; needle-tract seeding is uncommon (roughly 2.7%) and does not by itself preclude biopsy.
Treatment
Early-stage disease is managed with surgical resection, thermal ablation (tumors under 3 cm), or liver transplantation (Milan criteria). For intermediate disease, transarterial chemoembolization (TACE) is the standard. Advanced disease with vascular invasion is treated first-line with atezolizumab + bevacizumab (or durvalumab + tremelimumab, or nivolumab + ipilimumab); sorafenib or lenvatinib are alternatives when immunotherapy is contraindicated. Liver transplant is contraindicated in patients with extrahepatic spread.
Prognosis
Prognosis is dictated by the BCLC stage, which integrates tumor burden, performance status, and underlying liver function (Child-Pugh score). Portal vein thrombosis and rupture of the tumor are life-threatening complications. Patients require lifelong surveillance for recurrence post-resection.
Differential Diagnosis
Hepatic Adenoma: associated with oral contraceptive use
Focal Nodular Hyperplasia: central stellate scar on imaging
Hemangioma: most common benign liver tumor
Cholangiocarcinoma: presents with painless jaundice and elevated CA 19-9
Metastatic Liver Disease: usually multiple lesions rather than a single mass